Firmonertinib
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Firmonertinib
- Molecular weight
- 568.6
- Structure (SMILES)
- C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OCC(F)(F)F)nc1N(C)CCN(C)C
- afu
- AFU
- alflutinib
- Alflutinib
- ast 2818
- AST-2818
- ast2818
- AST2818
- firmonertinib
- Firmonertinib
- firmonertinib [INN]
- FIRMONERTINIB [USAN]
- Firmonertinib [WHO-DD]
- firmonertinib inn
- firmonertinib usan
- firmonertinib who dd
- furmonertinib
- Furmonertinib
- CAS registry numbers
- 1869057-83-9
- ChEMBL ID
- CHEMBL4297258
- InChIKey
- GHKOONMJXNWOIW-UHFFFAOYSA-N
- PubChem compound IDs
- 118861389
- FDA ingredient codes (UNII)
- A49A7A5YN4
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- firmonertinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Approval recorded by Guide to Pharmacology
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- epidermal growth factor receptor
- Gene symbol
- EGFR
- Protein identifier
- P00533
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
- Action type
- Inhibitor
- Target
- Epidermal growth factor receptor
- Protein identifier
- P00533
Open Targets mechanisms
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
- Action type
- Inhibitor
- Target
- Epidermal growth factor receptor
- Condition
- Adenocarcinoma of Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000571
- Subject identifier
- D000077192
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Lung Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition identifier
- EFO_0000571
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005288
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001012
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0008903
- Highest recorded phase
- 2
- NCT02973763
- NCT03452592
- NCT04853342
- NCT04858958
- NCT04895930
- NCT04958967
- NCT04970693
- NCT05165355
- NCT05209256
- NCT05255406
- NCT05334277
- NCT05379803
- NCT05430802
- NCT05445310
- NCT05465343
- NCT05466149
- NCT05548348
- NCT05813522
- NCT05987826
- NCT05994131
- NCT06319950
- NCT06339242
- NCT06394674
- NCT04965831
- NCT05079022
And 3 more, listed on the interactive page.
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 2
- Polar surface area
- 100.44
- Calculated partition coefficient (ALogP)
- 4.84
- Calculated partition coefficient (XLogP)
- 4.4
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 11
- Heavy atoms
- 41
- Molecular formula
- C28H31F3N8O2
- Monoisotopic mass
- 568.25220675
- Natural product
- No
- Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES.
Related records
Trials (65)
- A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC
- A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
- A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
- A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis
- A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression
- A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
- A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
- A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
- Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer
- Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
- AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
- Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）
- Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
- An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
- AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
- Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial
- ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas
- Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
- Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M
- Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)
In development for (4)
- Lung adenocarcinoma Phase 2
- Lung cancer Phase 2
- Neoplasm Phase 2
- Non-small cell lung carcinoma Phase 3
Targets (1)
- EGFR Epidermal growth factor receptor erbB1 inhibitor